Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Net Cash Flow (2017 - 2025)

Historic Net Cash Flow for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $1.9 million.

  • Sutro Biopharma's Net Cash Flow fell 9773.01% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$108.7 million, marking a year-over-year decrease of 21716.92%. This contributed to the annual value of $121.0 million for FY2024, which is 44975.02% up from last year.
  • Sutro Biopharma's Net Cash Flow amounted to $1.9 million in Q3 2025, which was down 9773.01% from -$42.2 million recorded in Q2 2025.
  • Sutro Biopharma's Net Cash Flow's 5-year high stood at $172.6 million during Q2 2023, with a 5-year trough of -$153.3 million in Q3 2023.
  • For the 5-year period, Sutro Biopharma's Net Cash Flow averaged around -$7.4 million, with its median value being -$293000.0 (2021).
  • In the last 5 years, Sutro Biopharma's Net Cash Flow plummeted by 2112727.27% in 2021 and then soared by 864808.36% in 2022.
  • Quarter analysis of 5 years shows Sutro Biopharma's Net Cash Flow stood at -$293000.0 in 2021, then plummeted by 16802.73% to -$49.5 million in 2022, then soared by 74.63% to -$12.6 million in 2023, then soared by 225.15% to $15.7 million in 2024, then tumbled by 87.91% to $1.9 million in 2025.
  • Its Net Cash Flow stands at $1.9 million for Q3 2025, versus -$42.2 million for Q2 2025 and -$84.1 million for Q1 2025.